Key facts
as of Oct 2026- Developer of surgical implant products containing human extracellular matrix and collagen designed for medical beauty.
- MayBio Biomedical is valued at approximately $11.4M as of Oct 2026 (last reported valuation).
- It has raised $2.9M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Hunan Chasing Fund, Alwin Capital, Century Golden Resources Group, Beijing New Aerotropolis Fund Management, Kefu Medical — 8 tracked in total.
- Status: Privately Held (backing).
Last reported valuation
LOW confidence$11.4M
MayBio Biomedical's last reported valuation, Aug 2020. Nothing priced has surfaced since.
Free account
More of MayBio Biomedical with a free account
- ·Watch MayBio Biomedical: the Monday email on marks, rounds and moves
Create free account
No card required
Funding rounds
No rounds on record
No funding rounds for MayBio Biomedical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Pro members can request priority coverage with a 48-hour turnaround.
About MayBio Biomedical
Developer of surgical implant products containing human extracellular matrix and collagen designed for medical beauty. The company is committed to providing a series of overall medical solutions including cells, biomaterials, human growth factors and human collagen, enabling medical professionals to have better medical products to use.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2019
- Website
- maybio.cn/
- Ownership
- Privately Held (backing)